Microvessel density, p53, retinoblastoma, and chromogranin a immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate

Urology

Volumn 55, Issue 5, 2000, Pages 743-749

  Krupski, Tracey ^a   Petroni, Gina R ^a   Frierson Jr , Henry F ^a   Theodorescu, Dan ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN; CHROMOGRANIN A; CHROMOGRANIN A, HUMAN; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CAPILLARY; CHEMISTRY; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MICROBIOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTION AND FORECASTING; PROSTATE TUMOR; PROSTATECTOMY; SURVIVAL RATE; VASCULARIZATION;

ADENOCARCINOMA; ADULT; AGED; CAPILLARIES; CHROMOGRANIN A; CHROMOGRANINS; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETINOBLASTOMA PROTEIN; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034186628     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00598-1     Document Type: Article

References (32)

1. Theodorescu D, Broder SR, Boyd JC, et al. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 158: 131-137, 1997.
2. Jackson MW, Bentel JM, and Tilley WD: Vascular endothelial growth lactor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 157: 2323-2328, 1997.
3. Paul R, Ewing CM, Jarrard DF, et al: The cadherin cell-cell adhesion pathway in prostate cancer progression. Br J Urol 79: 37-43, 1997.
4. Kallakury BV, Figge J, Ross JS, et al: Association of p53 immunoreactivity with high Gleason tumor grade in prostatic adenocarcinoma. Hum Pathol 25: 92-97, 1994.
5. Bookstein R, MacGrogan D, Hilsenbeck SG, et al: p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 53: 3369-3373, 1993.
6. Phillips SM, Barton CM, Lee SJ, et al: Loss of the retinoblastoma susceptibility gene (RBI) is a frequent and early event in prostatic tumorigenesis. Br J Cancer 70: 1252-1257, 1994.
7. Colombel M, Symmans F, Gil S, et al: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143: 390-400, 1993.
8. Van de Voorde WM, Elgamal AA, Van Poppel HP, et al: Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomies. Cancer 74: 3164-3175, 1994.
9. RossJS, Nazeer T, Figge HL, et al: Quantitative immunohistochemical determination of cathepsin D levels in prostatic carcinoma biopsies. Correlation with tumor grade, stage, PSA level, and DNA ploidy status. Am J Clin Pathol 104: 36-41, 1995.
10. Moul JW, Maygarden SJ, Ware JL, et al: Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy J Urol 155: 982-985, 1996.
11. Theodorescu D, Broder SR, Boyd JC, et al: Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 80: 2109-2119, 1997.
12. Gimbrone MA Jr, Leapman SB, Cotran RS, et al: Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 136: 261-276, 1972.
13. Mahadevan V, and Hart IR: Metastasis and angiogenesis. Acta Oncol 29: 97-103, 1990.
14. Volpert OV, Dameron KM, and Bouck N: Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene 14: 1495-1502, 1997.
15. Shurbaji MS, Kalbfleisch JH, and Thurmond TS: Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol 26: 106-109, 1995.
16. Kvanta A, Steen B, and Seregard S: Expression of vascular endothelial growth factor (VEGF) in retinoblastoma but not in posterior uveal melanoma. Exp Eye Res 63: 511-518, 1996.
17. Harper ME, Glynne-Jones E, Goddard L, et al: Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. Br J Cancer 74: 910-916, 1996.
18. Bostwick DG, Wheeler TM, Blute M, et al: Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology 48: 47-57, 1996.
19. Vartanian RK, and Weidner N: Endothelial cell proliferation in prostatic carcinoma and prostatic hyperplasia: correlation with Gleason's score, microvessel density, and epithelial cell proliferation. Lab Invest 73: 844-850, 1995.
20. Brawer MK, Deering RE, Brown M, et al: Predictors of pathologic stage in prostatic carcinoma. The role ofneovascularity. Cancer 73: 678-687, 1994.
21. Mills SE, and Fowler JE Jr: Gleason histologic grading of prostatic carcinoma. Correlations between biopsy and prostatectomy specimens. Cancer 57: 346-349, 1986.
22. Kaplan EL, and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-465, 1958.
23. Folkman J: The role of angiogenesis in tumor growth. Semin Cancer Biol 3: 65-71, 1992.
24. Liotta LA, Saidel MG, and Kleinerman J: The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res 36: 889-894, 1976.
25. Frank RE, Saclarides TJ, Leurgans S, et al: Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Ann Surg 222: 695-699, 1995.
26. Weidner N, Semple JP, Welch WR, et al: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
27. Bigler SA, Deering RE, and Brawer MK: Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol 24: 220-226, 1993.
28. Weidner N, Carroll PR, Flax J, et al: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401-409, 1993.
29. Silberman MA, Partin AW, Veltri RW, et al: Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 79: 772-779, 1997.
30. Gettman MT, Bergstralh EJ, Blute M, et al: Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: lack of significance for microvessel density analysis. Urology 51: 79-85, 1998.
31. Bettencourt MC, Bauer JJ, Sesterhenn IA, et al: Cd34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol 160: 459-465, 1998.
32. Dameron KM, Volpert OV, Tainsky MA, et al: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582-1584, 1994.